Balyasny Asset Management
TXG icon

Balyasny Asset Management’s 10x Genomics TXG Stock Holding History

Balyasny Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-65,000
Closed -$3.63M – 2809
2023
Q1 		$3.63M Buy
+65,000
New +$3.04M 0.01% 1205

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's TXG Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in 10x Genomics (TXG) in Q1 2026: 989,522 shares worth $21M. The stake represents 0.03% of the portfolio and ranks #672 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in TXG as recently as Q4 2024.

Balyasny Asset Management first reported a position in TXG in Q2 2020 and has held it in 10 quarters since. The position peaked at $37.8M in Q1 2023. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Balyasny Asset Management held 989,522 shares of 10x Genomics worth $21M as of Q1 2026.
  • 10x Genomics was a new Balyasny Asset Management position in Q1 2026.
  • 10x Genomics made up 0.03% of Balyasny Asset Management's portfolio in Q1 2026, its #672 holding.
  • Balyasny Asset Management first reported a position in 10x Genomics in Q2 2020 and has held it in 10 quarters since.
  • Balyasny Asset Management's 10x Genomics position peaked at $37.8M in Q1 2023.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.